What We Do
We are committed to curing all cancers
WE BUILD NETWORKS
Specifically, and with your assistance, we are attempting to:
— Promote Breakthrough Treatments
The Delivering Cures for Cancer Foundation was created to promote brand new and wholly innovative cancer treatments. In particular, we advocate a targeted tumor-specific delivery system that relies on nanomedicine, which we and others believe is the most promising therapy that now exists for curing cancer. This approach, developed by world-renowned Nanotechnologist and Oncologist, Dr. Esther Chang, is unlike any other treatment currently available because it places a bull’s eye specifically on cancer cells, greatly enhancing efficacy without damaging normal, healthy tissues and organs. By targeting cancer cells specifically, the treatment eliminates side effects commonly associated with chemotherapy while it delivers drugs, tumor-suppressing genes and other agents directly to tumors. This creates one of the most promising treatments ever developed.
We also recommend several new screening approaches that can detect cancers at very early stages when lives can be saved.
— Advocate for Patients
At Delivering Cures for Cancer, we serve as patient advocates, raising the standard of care for every person suffering from cancer, regardless of socioeconomic or cultural background. We are also very concerned with the costs of cancer treatment. Both screening for early detection and the delivery system for the revolutionary treatment are very cost-effective approaches. Effective screening eliminates the far-higher costs of late stage therapy, while the delivery system eliminates most costs associated with side effects.
Get the latest updates on our research.
Delivering Cures for Cancer
4701 Randolph Rd.
Rockville MD 20852
*All donations are tax deductible.
OR DONATE ONLINE
support us and changethe future of cancer.
Drs. Ronald Shore and Joseph Fox, who founded Delivering Cures for Cancer and The Paula Shore/Sari Fox Foundation, receive no salary, income or other compensation from the Foundation. Their donations have covered the majority of the start up costs including website, legal, accounting, administrative, and promotions expenses. Dr. Shore, whose skin cancer screening program is described on this website, has helped to educate fellow dermatologists and other medical personnel on how to perform highly effective skin cancer screening through international lectures and publications, largely at personal expense. Honoraria for his presentations, if provided, have been returned to the institution (e.g. University of Pennsylvania), or given to charity (e.g. The Society for Dermatologic Physician Assistants). He receives no other compensation from industry, academic institutions or other entities. Dr. Shore has volunteered his time and knowledge on screening to 20/20 GeneSystems, Inc., the developer of the PAULAs Test, a new blood test for early detection of lung cancer. He has also served on its Medical Advisory Board. He has received no remuneration for these forms of assistance. Dr. Shore and Dr. Fox were each approached by 20/20 GeneSystems, Inc. to purchase shares to help the company continue its research, and both agreed to do so. Their investments in the company, in each case, represent well under 1% of total investments. Neither physician holds any controlling or voting position in the company, nor draws any salary or other compensation. Dr. Shore and Dr. Fox, who for several years have spoken to various individuals, organizations and government personnel to try to advance Dr. Esther Chang’s research, were each approached by SynerGeneTherape